EWTX vs SRRK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
EWTX · Edgewise Therapeutics$45.04 ▲ 15.87%
SRRK · Scholar Rock$46.94 ▲ 3.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- EWTX +146.4%
- SRRK +59.8%
Head to head
| Metric | EWTX | SRRK |
|---|---|---|
| Price | $45.04 | $46.94 |
| Change today | ▲ 15.87% | ▲ 3.16% |
| Market cap | $4.93B | $5.72B |
| Return, 3 months | +1.0% | -9.5% |
| Return, year to date | +81.5% | +6.6% |
| Return, 1 year | +162.5% | +62.1% |
| P/E (TTM) | 5.4 | – |
| P/B | 3.0 | 22.5 |
| P/E percentile vs own 5y | 11th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -58.7% | +0.1% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -38.0% | -167.8% |
| Analyst target vs. price | +23.1% | +49.1% |
| Analyst buy share | 100% | 93% |
| RSI (14) | 68 | 60 |
| 30-day volatility | 56.7% | 42.7% |
| Max drawdown, 1 year | -25.0% | -34.0% |
| Trend read | Strong uptrend | Mixed |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SRRK is the largest of the group by market value.
- EWTX has returned the most over the past year.
- SRRK has been the calmest stock over the last 30 days.